Drug intelligence / Profile preview

Canavia

Development stage: Unknown
Lead developer: Arian Salamat Sina
Modality: Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Administration: Topical

Overview

Canavia is a topical pain relief cream developed and manufactured by Arian Salamat Sina. It is formulated with 1.5% cannabidiol (CBD) extracted from hemp, along with natural botanical extracts including Arnica montana, rosemary, peppermint oil, shea butter, and vitamin C. The cream is designed to alleviate chronic pain, muscle spasms, joint discomfort, and localized inflammation. It is free of tetrahydrocannabinol (THC) and parabens, ensuring a non-psychoactive and safe profile for topical application.

Brand names: Canavia
Other names: Canavia CBD Creamکرم ضد درد کاناویا

Targets

TRPV1 (Transient receptor potential cation channel subfamily V member 1)CNR1 (Cannabinoid receptor 1)

Beyond the preview

Go deeper on Canavia.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Canavia.

Explore the full profile